Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
CHITOGENX Aktie jetzt für 0€ handeln | |||||
09.09. | Chitogenx Inc: Chitogenx enters LOI for reverse takeover with Oligo | 1 | Stockwatch | ||
09.09. | Chitogenx Announces Signing Of Binding Letter Of Intent With Oligo Medic Inc., Issuance Of Partial Revocation Order, And Financing | 1 | CNW | ||
09.06. | Chitogenx Inc: Chitogenx suspended by CSE | 2 | Stockwatch | ||
09.06. | CSE Bulletin: Suspensions - ChitogenX Inc., Shoal Point Energy Ltd., The Yumy Candy Company Inc. | 774 | Newsfile | Toronto, Ontario--(Newsfile Corp. - Le 9 juin/June 2025) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as... ► Artikel lesen | |
09.06. | Chitogenx Inc: Chitogenx halted at the open | 1 | Stockwatch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ADMA BIOLOGICS | 13,990 | -0,50 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
ARCELLX | 85,21 | +0,95 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
CG ONCOLOGY | 38,000 | -0,24 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
QIAGEN | 40,155 | +0,06 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
GALECTO | 17,990 | +384,91 % | Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble | ||
ARVINAS | 9,300 | -3,23 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
COGENT BIOSCIENCES | 15,440 | -2,89 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
BIONTECH | 91,00 | +1,34 % | Pfizer prescht nach vorne, BioNTech gerät unter Druck, Eli Lilly feiert eine neue Zulassung und AstraZeneca zieht es nach New York | Wieder einmal überschlagen die Dinge sich in der US-Politik, wobei das Thema Gesundheit eine wichtige Rolle spielt. Reibereien über die staatliche Gesundheitsfürsorge gelten als einer der Hauptgründe... ► Artikel lesen | |
DISC MEDICINE | 67,89 | -2,01 % | Disc Medicine Inc: Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) | Disc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30,... ► Artikel lesen | |
EVOTEC | 6,778 | -1,74 % | Evotec-Aktie: Das sah schon schlechter aus! Jetzt einsteigen? | © Foto: CDC auf UnsplashVom Hamburger Wirkstoffforscher Evotec war in den vergangenen Wochen nur wenig zu hören. Der Aktie hat das nicht geschadet, im Gegenteil.
Evotec: Die Ruhe hat der Aktie nicht... ► Artikel lesen | |
TOURMALINE BIO | 47,890 | +0,03 % | Novartis Pharma AG: Novartis announces commencement of tender offer to acquire Tourmaline Bio | Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ("Purchaser"), has commenced a tender offer... ► Artikel lesen | |
STRUCTURE THERAPEUTICS | 28,420 | -0,91 % | Aktien New York: Weitere Rekorde - auch dank Nvidia und Apple | NEW YORK (dpa-AFX) - Die US-Börsen haben am Montag nach einem verhaltenen Start ihre Rekordjagd fortgesetzt. Auch dank deutlicher Kursgewinne der Schwergewichte Nvidia und Apple verzeichnete der Leitindex... ► Artikel lesen | |
MAZE THERAPEUTICS | 27,860 | +1,31 % | Maze Therapeutics, Inc.: Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors | SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,225 | -5,43 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 9,280 | +6,91 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen |